IP Library Granted Patent US 9,271,937
Granted Patent B2
US 9,271,937 · App. 13/903,297 · Granted Mar 1, 2016

Oxidized cellulose microspheres

Inventors: Phillip Blaskovich (Salem, MA); Valentino Tramontano (Brockton, MA); Joshua Kennedy (Somerville, MA); Rachit Ohri (Framingham, MA)
Assignee: Covidien LP
A61K9/1652A61K9/1682A61K9/1694A61K31/445A61K31/714A61K33/24B01J13/12B01J13/125
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,271,937
App. No.
13/903,297
Granted
Mar 1, 2016
Kind
B2
Abstract

A process for forming microspheres is disclosed. The process includes contacting a solvent with a modified cellulose to form a solution; contacting the modified cellulose solution with at least one bioactive agent to form a discontinuous phase liquid; contacting the discontinuous phase liquid with a continuous phase liquid to form an emulsion; and contacting the emulsion with a third phase liquid to extract the solvent from the emulsion, thereby forming a plurality of modified cellulose microspheres.

Claims (26)

1. A process for forming microspheres comprising:

contacting a solvent with a modified cellulose to form a modified cellulose solution;

contacting the modified cellulose solution with at least one bioactive agent to form a discontinuous phase liquid;

contacting the discontinuous phase liquid with a continuous phase liquid to form an emulsion, the continuous phase is selected from the group consisting of plant-based oils, petroleum-based oils, silicone-based oils, and combinations thereof; and

contacting the emulsion with a third phase liquid to extract the solvent from the emulsion, thereby forming a plurality of modified cellulose microspheres.

2. The process according to claim 1 , wherein the third phase liquid is miscible with the continuous phase liquid and the discontinuous phase liquid.

3. The process according to claim 2 , wherein the third phase liquid is selected from the group consisting of isopropyl myristate, hexane, triglycerides and combinations thereof.

4. The process according to claim 3 , wherein the third phase liquid is present in an amount from about 130% by volume to about 170% by volume of the continuous phase liquid.

5. The process according to claim 1 , wherein formation of the modified cellulose solution comprises:

contacting the modified cellulose with the solvent under an inert atmosphere to form a swelled modified cellulose;

adjusting the swelled modified cellulose mixture to a first temperature;

contacting the swelled modified cellulose after adjusting the first temperature with a salt under the inert atmosphere to form a modified cellulose solution; and

adjusting the modified cellulose solution to a second temperature.

6. The process according to claim 5 , wherein the first temperature is from about 115° C to about 145° C and the second temperature is from about 90° C to about 120° C.

7. The process according to claim 1 , wherein the solvent is selected from the group consisting of N,N-Dimethylacetamide, N-methyl-2-pyrrolidinone, and combinations thereof.

8. The process according to claim 6 , wherein the salt is selected from the group consisting of lithium halides, sodium halides, potassium halides, and combinations thereof.

9. The process according to claim 1 , further comprising:

contacting the plurality of modified cellulose microspheres with a solution of a biodegradable polymer and an aqueous solution to form an emulsion; and

extracting a plurality of biodegradable polymer microspheres encapsulating the plurality of modified cellulose microspheres.

10. The process according to claim 9 , wherein the biodegradable polymer is an aliphatic polyester.

11. The process according to claim 10 , wherein the aqueous solution comprises at least one emulsifier and water.

12. The process according to claim 1 , wherein the at least one bioactive agent is hydrophilic.

13. The process according to claim 1 , wherein the third phase liquid is miscible with the continuous phase liquid and immiscible with the discontinuous phase liquid.

14. The process according to claim 13 , wherein the third phase liquid is present in an amount from about 8.33% by volume to about 11.11% by volume of the continuous phase liquid.

15. The process according to claim 13 , wherein the third phase liquid is present in an amount from about 6.25% by volume to about 11.11% by volume of the continuous phase liquid.

16. The process according to claim 2 , wherein the third phase liquid is present in an amount from about 8.33% by volume to about 11.11% by volume of the continuous phase liquid.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 14, 2014
From: CONFLUENT SURGICAL, INC.
To: COVIDIEN LP
Reel/Frame 031957/0415 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2013
From: BLASKOVICH, PHILLIP; TRAMONTANO, VALENTINO; KENNEDY, JOSHUA; OHRI, RACHIT
To: CONFLUENT SURGICAL, INC.
Reel/Frame 031007/0579 →
Continuity (2)
Provisional Application 61653620 · May 31, 2012
Related Publication 20130323315A1 · Dec 5, 2013